vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $55.25.

Several analysts recently weighed in on the company. BTIG Research reissued a “buy” rating and set a $49.00 price target (up from $40.00) on shares of vTv Therapeutics in a report on Tuesday. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Roth Mkm assumed coverage on vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. Finally, TD Cowen began coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating on the stock.

vTv Therapeutics Price Performance

Shares of VTVT stock opened at $34.15 on Friday. The company has a fifty day moving average price of $34.27 and a two-hundred day moving average price of $25.07. The stock has a market cap of $134.55 million, a P/E ratio of -10.29 and a beta of 0.48. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP raised its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after acquiring an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.